Arsinothricin as a multi-stage antimalarial
The subject invention provides arsinothricin (AST) or salts thereof, and compositions comprising AST or a salt thereof for use as multi-stage antimalarials. The subject invention also provides methods for treating, inhibiting and/or preventing malaria infection and transmission by using AST or salts thereof, or compositions comprising AST or a salt thereof. Advantageously, AST or a salt thereof inhibits glutamine synthetase (GS) of malaria pathogens without exhibiting cytotoxicity to human host.
1. A method of treating malaria infection in a subject in need thereof comprising administering to the subject arsinothricin (AST) or a salt thereof.
2. The method of claim 1 , the malaria being caused by P. falciparum, P. malariae, P. ovale, P. vivax, P. knowlesi, P. berghei, P. chabaudi or P. yoelii.
3. The method of claim 1 , the administration being via oral, pulmonary, buccal, suppository, intravenous, intraperitoneal, intranasal, intramuscular, or subcutaneous route.
4. The method of claim 1 , the salt of AST being:
i) with an acid selected from hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid (TFA), formic acid, acetic acid, propionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-di sulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid;
ii) with a base selected from sodium hydroxide, ammonium hydroxide, potassium hydroxide, monoalkyl amine, dialkyl amine, trialkyl amine, aryl amine, ammonium, and tetraalkylammonium; or
iii) with a metal selected from sodium, potassium, calcium, and magnesium.
5. The method of claim 1 , the subject being a human.
6. The method of claim 1 , the AST being L-AST.
7. The method of claim 1 , the method further comprising detecting the activity of glutamine synthetase (GS) of the malaria parasite.
8. A method of inhibiting or reducing malaria transmission, the method comprising administering to a subject arsinothricin (AST) or a salt thereof.
9. The method of claim 8 , the subject being a human having been infected by a malaria parasite.
10. The method of claim 9 , the malaria parasite being P. falciparum, P. malariae, P. ovale, P. vivax, P. knowlesi, P. berghei, P. chabaudi or P. yoelii.
11. The method of claim 8 , the administration being via oral, pulmonary, buccal, suppository, intravenous, intraperitoneal, intranasal, intramuscular, or subcutaneous route.
12. The method of claim 8 , the AST being L-AST.
13. The method of claim 8 , the salt of AST being:
i) with an acid selected from hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid (TFA), formic acid, acetic acid, propionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-di sulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid;
ii) with a base selected from sodium hydroxide, ammonium hydroxide, potassium hydroxide, monoalkyl amine, dialkyl amine, trialkyl amine, aryl amine, ammonium, and tetraalkylammonium; or
iii) with a metal selected from sodium, potassium, calcium, and magnesium.
14. The method of claim 8 , the method further comprising detecting the activity of GS of the malaria parasite.
15. A method of inhibiting or reducing the growth of malaria parasite in a subject having malaria, the method comprising administering to the subject AST or a salt thereof.
16. The method of claim 15 , the subject being a human.
17. The method of claim 15 , the malaria parasite being P. falciparum, P. malariae, P. ovale, P. vivax, P. knowlesi, P. berghei, P. chabaudi or P. yoelii.
18. The method of claim 15 , the administration being via oral, pulmonary, buccal, suppository, intravenous, intraperitoneal, intranasal, intramuscular, or subcutaneous route.
19. The method of claim 15 , the AST being L-AST.
20. The method of claim 15 , the method further comprising detecting the activity of GS of the malaria parasite.